Drafting Perfect 483 Responses: The New FDA Guidelines Explained. FDA Form 483 observations are issued when investigators identify conditions that may violate cGMP requirements.
Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: This article discuss why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How. Visit us for more…
The Algorithm of Biopharma Compliance in Canada : Navigating Health Canada’s AI Regulatory Shift In the fast-evolving landscape of Canadian life sciences where “innovation” is no longer just about the molecule. It’s about the machine.
Tagged : AI, APQR, Biopharmaceutical, Compliance, Data Integrity, Digital Transformation, GxP, Health Canada, quality, Quality 4.0
How to Maximize Compliance in 2026 with AI-Assisted APQR Products. Discover how to leverage low-code apps for data integrity in the 2026 Compliance Revolution and enhance your APQR process to take advantage of AI-Assisted Products.
Tagged : AI, APQR, Biopharma, Biopharmaceutical, Compliance, Digital Transformation, GxP, Pharma 4.0, quality, Quality 4.0
Navigating the Pitfalls of MSAT for Successful Technology Transfer: In the biopharmaceutical sector, MS&T responsibilities extend to both upstream and downstream processes. This includes optimizing cell culture conditions, managing bioreactor performance, and ensuring effective purification